| Thursday, October 19, 2006 |
| 7:00am - 8:00am |
Continental Breakfast
8:00am - 8:15am OPENING REMARKS
Jay Skyler, MD |
| 8:15am - 9:00am |
KEYNOTE PRESENTATION
Assessing Global CVD and Type 2 Diabetes Risk: From Metabolic Syndrome
to Cardiometabolic Risk
Jean-Pierre Després, PhD
• Clear the confusion between the conceptual definition of the metabolic syndrome vs. the clinical criteria
to identify individuals with the metabolic syndrome
• Review evidence that visceral obesity is, in clinical practice, the most prevalent form of insulin resistant state
• Discuss the need to incorporate metabolic syndrome in global cardiovascular disease risk assessment
• Introduce "hypertriglyceridemic waist" as a useful and simple phenotype defining a subgroup of obese
patients with the features of the metabolic syndrome increasing the risk of type 2 diabetes and
cardiovascular diseases, such global risk being defined as cardiometabolic risk |
| 9:00am - 9:30am |
Biomarkers for Cardiometabolic Risk Assessment in Clinical Practice
Robert Eckel, MD
• What biomarkers belong to “The Cheap and Easy”?
• The “Expanding Horizon” of biomarkers: What is reasonable and at least somewhat informative?
• What are the biomarkers of increasing interest, but not ready for prime time? |
| 9:30am - 10:00am |
Inflammation: Etiology and Biomarkers
Christie Ballantyne, MD
• Review the evidence that inflammation occurs in adipose tissue with obesity
• Appreciate the mechanism by which inflammation in adipose tissue may lead to insulin resistance
• Discuss how inflammation in adipose tissue can accelerate atherosclerotic vascular disease
• Understand that inflammation is a critical link for cardiometabolic risk |
| 10:00am - 10:30am |
Exhibit Hall/Morning Break |
| 10:30am - 11:00am |
CLINICAL TRIALS UPDATE
Assessing the Evidence and Effectiveness of Current and Emerging
Therapies in Clinical Practice
Moderator: Christie Ballantyne, MD
Current and Emerging Therapies for Obesity
Louis Aronne, MD
• Understand the current research in obesity and how it will impact the future of obesity treatment
• Understand the neuroendocrine aspects of obesity and how this contributes to the difficulty of obese
patients to lose and maintain weight
• Understand the mechanism of action and clinical aspects of pharmacologic agents in development to treat obesity
|
| 11:00am - 11:30am |
Current and Emerging Therapies for Hypertension
Matthew Weir, MD
• Understand the rationale behind lower blood pressure goals and reduced risk for cardiovascular events
• Understand the results of clinical trials such as HOPE and ALLHAT and how they influence guidelines
and decision making in hypertension therapeutics
• Appreciate the need for individualizing blood pressure goals, understanding cardiovascular comorbidity,
and the requirement for multiple antihypertensive medications for achievement of blood pressure goals
• Understand the need for lower blood pressure goals in patients with cardiovascular or renal disease, or
diabetes mellitus
• Appreciate the need for performing new clinical trials to evaluate optimal combinations of medications to
facilitate lower blood pressure goals and reduce cardiovascular events |
| 11:30am - 12:00pm |
Current and Emerging Therapies for Dyslipidemia
Christopher Cannon, MD
• Become familiar with new data on intensive statin therapy
• Understand current data on the mechanism of action of statin therapy
• Learn of new non-statin therapies, including fibrates and ezetimibe |
| 12:00pm - 12:30pm |
Current and Emerging Therapies for Type 2 Diabetes
David Nathan, MD
• Understand the magnitude and causes of the type 2 diabetes epidemic
• Recognize the demonstrated benefits of intensive management of glycemia, demonstrated in clinical
trials, as it relates to long-term complications
• Understand the relative advantages and disadvantages of the currently available diabetes interventions
• Learn the recently recommended algorithm for the metabolic management of type 2 diabetes |
| 12:30pm - 1:45pm |
LUNCH SYMPOSIUM
Cardiometabolic Risk Reduction: Targeting Abdominal Adiposity and the
Endocannabinoid System
Louis Aronne, MD; Robert Eckel, MD; Richard Nesto, MD |
| 1:45pm - 2:15pm |
Glitazones: What Is Their Role in Cardiometabolic Risk Management?
Jorge Plutzky, MD
• Understand PPARs and their mechanism of action and use as a drug target
• Review the existing basic science and clinical data that provides a rationale for considering
PPAR-gamma activation by thiazolidinediones as a treatment for cardiometabolic risk
• Consider the limitations in thiazolidinediones as a treatment for metabolic syndrome
• Discuss future options in PPAR targeting for the treatment of cardiometabolic risk |
| 2:15pm - 3:15pm |
DISCUSSION & DEBATE
LDL, Triglycerides, and HDL: Which Risk Factors Are Most Important?
Moderator: Christie Ballantyne, MD
Panelists: Stephen Wiviott, MD; Frank Sacks, MD; Christopher Cannon, MD |
| 3:15pm - 3:45pm |
Afternoon Break/Exhibit Hall |
| 3:45pm - 4:15pm |
Prevention, Treatment, and Control of Type 2 Diabetes
Vivian Fonseca, MD
• Understand the impact of insulin resistance on the development and progression of type 2 diabetes and
cardiovascular disease
• Evaluate clinical trial data to suggest that it is possible to prevent diabetes in patients with the metabolic
syndrome using a variety of medications in addition to lifestyle change
• Examine the impact of insulin sensitizer therapy on the risk of cardiovascular disease in patients with
pre-diabetes and the metabolic syndrome |
| 4:15pm - 4:45pm |
The Patient with Diabetes and Heart Disease: Strategies to Prevent a Second Coronary Event
Richard Nesto, MD
• Identification of cardiometabolic risk factors responsible for coronary events in the patients considered to
be "adequately" managed according to current guidelines
• Overweight and obesity as a target "organ" for modification beyond traditional risk factors for
cardiovascular risk |
| 4:45pm |
CLOSING REMARKS
Jay Skyler, MD |
| 5:00pm - 6:30pm |
WELCOME RECEPTION IN EXHIBIT HALL |
Friday, October 20, 2006 |
| 7:00am - 8:00am |
BREAKFAST SYMPOSIUM
Inhibiting RAAS at the Point of Activation: A Novel Antihypertensive Therapeutic Option |
| 8:00am - 8:15am |
OPENING REMARKS
Christie Ballantyne, MD |
| 8:30am - 9:15am |
KEYNOTE PRESENTATION
Insulin Resistance, Obesity, and Type 2 Diabetes
C. Ronald Kahn, MD
• Review how insulin works and how insulin resistance occurs
• Understand how insulin resistance in different tissues can contribute different parts of the metabolic
syndrome of diabetes
• Describe the unique role of insulin resistance in fat |
| 9:15am - 9:45am |
How to Assess Quality in Clinical Practice
Thomas Lee, MD
• Describe market forces that are promoting the use and public reporting of measures for quality of
cardiovascular care
• Describe the major quality measures for physician care of patients at increased cardiometabolic risk
• Describe the most important tools and systems that can be used to capture data and improve quality
of care for patients at increased cardiometabolic risk |
| 9:45am - 10:15am |
Morning Break/Exhibit Hall |
| 10:15am - 11:15am |
DISCUSSION & DEBATE
Do Current Guidelines Accurately Identify Cardiometabolic Risk?
Moderator: Richard Nesto, MD
Panelists: Christie Ballantyne, MD; Robert Eckel, MD; Richard Kahn, PhD; F. Xavier Pi-Sunyer, MD |
| 11:15am - 12:30am |
DISCUSSION & DEBATE
Visceral Fat vs. Liver Fat vs. Muscle Fat: Where Does the Problem Arise?
Moderator: Jay Skyler, MD
Panelists: Jean-Pierre Després, PhD; Gerald Shulman, MD; David Kelley, MD
12:30pm - 1:45pm LUNCH SYMPOSIUM
The Role of DPP-IV Inhibition in Achieving Glycemic Control |
| 1:45pm - 2:15pm |
CONCURRENT SESSIONS
Cardiometabolic Risk in Children: How Should It Be Defined, Who Does It Affect,
and What Should We Do?
Francine Kaufman, MD
• Understand how cardiometabolic risk is defined in children
• Be familiar with cardiometabolic risk factors in children
• Understand treatment/intervention strategies |
| 1:45pm - 2:15pm |
Cardiometabolic Risk in High-Risk Populations
John Foreyt, PhD
• Define the components of cardiometabolic risk in high-risk populations
• Evaluate current therapies for the management of cardiometabolic risk in high-risk populations
• Discuss successful lifestyle modification programs for high-risk patients |
| 2:15pm - 3:15pm |
Emerging Technologies: Assessment of Screening Tools and Their Role in Clinical Practice
Moderator: Christie Ballantyne, MD
Presenters: Richard Nesto, MD; Paolo Raggi, MD
• Assess current modalities to screen for subclinical CAD in diabetic patients
• Identify appropriate patients for screening and risk quantification for CHD
• Understand the utility of modern imaging technologies to better define risk in the metabolic syndrome
• Appreciate the appropriate indications for imaging as a tool to assess cardiovascular risk |
| 2:15pm - 2:45pm |
CONCURRENT SESSIONS CONTINUED
Exercise, AMPK, and the Treatment and Prevention of the Metabolic Syndrome
Neil Ruderman, MD
• Understand the biochemistry of AMP-activated protein kinase
• Become aware of the relationship between physical activity and the prevalence of type 2 diabetes,
premature cardiovascular disease, and other disorders associated with the metabolic syndrome
• Become familiar with the AMPK/malonyl CoA fuel sensing and signaling mechanism and how it is
affected by exercise
• Review the evidence that dysregulation of AMPK/malonyl CoA underlies a wide variety of disorders
associated with insulin resistance and altered lipid metabolism in rodents
• Review the evidence that AMPK and malonyl CoA are targets for treating the metabolic syndrome |
| 2:45pm - 3:15pm |
Fat vs. Carbohydrates vs. Protein: What Type of Diet Should You Recommend to Your Patients?
Frank Sacks, MD
• Learn how dietary fats, carbohydrates, and protein affect differently LDL cholesterol, the primary lipid target
• Learn how dietary fats, carbohydrates, and protein affect triglycerides and HDL cholesterol, the
independent lipid risk factors of the metabolic syndrome
• Learn what diet types are most effective for weight loss
• Combine objectives 1–3 to formulate the most effective dietary approaches to reduce cardiovascular risk |
| 3:15pm - 3:45pm |
Afternoon Break/Exhibit Hall |
| 3:45pm - 4:45pm |
Strategies for Improving Patient Compliance to Diet, Lifestyle, and Medical Therapies
Moderator: F. Xavier Pi-Sunyer, MD Presenters: William Kraus, MD; Nancy Miller, RN BSN
• Understand the importance of using a cognitive model in the clinic setting to underlie counseling about
lifestyle interventions
• Understand how a clinic environment supporting lifestyle change can be incorporated into a clinic model
• Understand the importance of encouraging exercise as an effective therapy for cardiometabolic risk
• Identify strategies to attain dietary change and physical activity compliance |
| 3:45pm - 4:45pm |
Bariatric Surgery: Patient Selection, Procedure Options, and Long-Term Outcomes
Moderator: Christie Ballantyne, MD Presenters: Kenneth MacDonald, MD; Matthew Hutter, MD
• Understand which patients might benefit from weight-loss surgery
• Review the criteria and the processes involved in patient selection
• Understand the options available for weight-loss surgery, including the anatomy and physiology,
and procedure-related specifics
• Evaluate the short- and long-term outcomes for the different weight-loss procedures, including
complications and mortality, weight-loss over time, and reduction in weight-related comorbid illnesses |
| 4:45pm - 5:15pm |
CLOSING SESSION
Strategies for the Prevention of Heart Disease in Patients with Type 2 Diabetes
Jay Skyler, MD
• Summarize the various ways in which cardiovascular disease evolves in patients with type 2 diabetes
• Develop intervention strategies to reduce cardiovascular disease risk in patients with type 2 diabetes |
| 5:15pm |
CLOSING REMARKS
Richard Nesto, MD |
Saturday, October 21, 2006 |
| 7:00am - 8:15am |
Continental Breakfast |
|
|
| 8:30am - 9:30am |
CONCURRENT SESSIONS
MEET-THE-EXPERT SESSION
Disease Prevention: Establishing and Integrating Necessary Lifestyle Changes
Scott Urquhart, PA-C; William Kraus, MD
• Know the risk factors and counterproductive lifestyles leading to obesity and the subsequent medical
conditions associated with it
• Gain insight into the physical and emotional difficulties that obese patients face on a daily basis in order
to enhance your therapeutic approach
• Create inquisitive interviewing skills, treatment options, and follow-up plans
• Implement positive lifestyle changes, articulate relapse prevention, and set obtainable goals to promote
successful weight loss and maintenance |
|
|
| 8:30am - 9:30am |
MEET-THE-EXPERT SESSION
Metabolic Syndrome as a Predictor of Type 2 Diabetes
Steven Haffner, MD
• Learn about definitions of the metabolic syndrome
• Explore the controversies about the metabolic syndrome deriving from the ADA position statement in 2005
• Learn about the risk of the metabolic syndrome for patients with cardiovascular disease and type 2 diabetes |
|
|
| 9:30am - 10:00am |
Exhibit Hall/Morning Break |
|
|
| 10:00am - 11:00am |
MEET-THE-EXPERT SESSION
Optimizing the Care of the Cardiometabolic Patient in the Hospital and
Post-Hospitalization Setting
Richard Nesto, MD
• Evaluate the role of hyperglycemia in hospitalized patients as a factor responsible for morbidity and mortality
• Learn about the importance of insulin as an agent to minimize hyperglycemia in this setting
• Critically review the data related to GIK and other regimens to treat metabolic risk in hospitalized patients |
| 10:00am - 11:00am |
CHALLENGING CASE STUDIES SESSION
Challenging Case Studies in Metabolic Syndrome
F. Xavier Pi-Sunyer, MD |
|
|
|
|
|
|
|
|
|
|
| 11:00am - 12:00pm |
CHALLENGING CASE STUDIES SESSION
Challenging Case Studies in Bariatric Surgery Patient Selection
Matthew Hutter, MD
|
| 11:00am - 12:00pm |
CHALLENGING CASE STUDIES SESSION
Cardiometabolic |
Join Our Mailing List
2011 Congress Details
2011 Online CME Activity
Useful Links
Recommend This Site 
